Even on the contentious topic of orphan drug pricing, the last few months have brought hopeful signs that patients, pharmaceutical companies, health insurers, and the academic bodies that counsel them are trying to speak the same language.
Leslie Isenegger
Advertisement
Articles by Leslie Isenegger
Advertisement
Latest Updated Articles
- Can A New Value Framework Help Ease Friction Over Orphan Drug Prices?
Published: September 7th 2017 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Lilly and Novo Nordisk Bring GLP-1s to TrumpRX
2
FDA Approves Johnson and Johnson’s Darzalex Faspro for Adults with High-Risk Smoldering Multiple Myeloma
3
FDA Continues to Expand National Priority Voucher Program
4
Will Pharma’s Direct-to-Patient Push Disintermediate Wholesalers?
5
